Theresa L. Werner, MD

Journal Article

1. Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S (2022). First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Invest New Drugs.
2. Dang C, Ewer MS, Delaloge S, Ferrero J, Colomer R, Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, Sarkar S, Haas S, Restuccia E, Swain S (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab. Cancers, 14(11), 2596.
3. Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF (2022). Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer, 10(3).
4. Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH (2021). Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun, 12(1), 3039.
5. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, OMalley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM (2021). Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(2), 191-226.
6. Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, DAmelio AM Jr, Ellis C, Ibrahim N, Yan L (2020). Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol.
7. McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, Werner TL, Gaffney DK (2019). The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol, 156(1), 85-92.
8. Harris KL, Maurer KA, Jarboe E, Werner TL, Gaffney D (2019). LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT? Gynecol Oncol, 156(1), 243-250.
9. Boothe D, Orton A, Kim J, Poppe MM, Werner TL, Gaffney DK (2019). Does Early Chemotherapy Improve Survival in Advanced Endometrial Cancer? Am J Clin Oncol, 42(11), 813-817.
10. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med.
11. Mirza MR, vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, r Knudsen A, Staff S, Krog Vistisen A, Bjrge L, Menp JU, AVANOVA investigators (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol.
12. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, OMalley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM (2019). NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw, 17(8), 896-909.
13. Blackburn BE, Soisson S, Rowe K, Snyder J, Fraser A, Deshmukh V, Newman M, Smith K, Herget K, Kirchhoff AC, Kepka D, Werner TL, Gaffney D, Mooney K, Hashibe M (2019). Prognostic factors for rural endometrial cancer patients in a population-based cohort. BMC Public Health, 19(1), 921.
14. Ager BJ, Francis SR, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK (2019). Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?LID - S1538-4721(18)30764-5 [pii]LID - 10.1016/j.brachy.2019.03.001 [doi]. Brachytherapy, 18(4), 453-461.
15. Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer.
16. Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer.
17. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Al-Sarray A, Werner TL, Setiawan VW, Hashibe M (2018). Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study. J Natl Cancer Inst, 110(12), 1342-1351.
18. Gaffney DK, Hasibe M, Kepka D, Maurer KA, Werner TL (2018). Too many women are dying from cervix cancer: Problems and solutions. Gynecol Oncol.
19. Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697.
20. Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR (2018). Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med, 7(6), 2360-2369.
21. Park J, Blackburn BE, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Burt L, Werner TL, Gaffney DK, Lopez A, Mooney A (2018). Rural-metropolitan disparities in ovarian cancer survival: A statewide population-based study. Ann Epidemiol.
22. Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Hanson HA, Wu YP, Stanford J, Werner TL, Setiawan VW, Hashibe M (2018). Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecol Oncol, 148(3), 499-506.
23. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C (2018). Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol, 29(3), 646-653.
24. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2018). Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
25. Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janat-Amsbury MM (2018). Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. Int J Gynecol Cancer, 28(1), 152-160.
26. Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer, 17(7), 503-509.
27. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, Reddy CB, Boltax JP, Li DY, Moos PJ, Gray JW, Heiser LM, Buys SS, Cohen AL, Johnson WE, Quinlan AR, Marth G, Werner TL, Bild AH (2017). Combating subclonal evolution of resistant cancer phenotypes. Nat Commun, 8(1), 1231.
28. Mackay DR, Howa AC, Werner TL, Ullman KS (2017). Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. J Cell Sci, 130(19), 3347-3359.
29. Boothe D, Williams N, Odei B, Poppe MM, Werner TL, Suneja G, Gaffney DK (2017). The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer: Survival Outcomes and Patterns of Care. Int J Gynecol Cancer, 27(5), 912-922.
30. Odei B, Boothe D, Suneja G, Werner TL, Gaffney DK (2017). Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival [Epub ahead of Print]. Am J Clin Oncol.
31. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
32. Willmore-Payne C, Damjanovich-Colmenares K, Pasi AV, Werner TL, Gulbahce HE, Downs-Kelly E, Geiersbach KB (2016). Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status. Am J Clin Pathol, 146(5), 618-626.
33. Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemother Pharmacol, 78(3), 491-500.
34. Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M (2016). Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 14(9), 1134-63.
35. Boothe D, Orton A, Odei B, Stoddard G, Suneja G, Poppe MM, Werner TL, Gaffney DK (2016). Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival. Gynecol Oncol, 141(3), 421-427.
36. Geiersbach K, Willmore-Payne C, Pasi Av, Paxton C, Werner TL, Xu X, Wittwer CT, Gulbahce HE, Downs-Kelly E (2016). Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Am J Clin Pathol, Oct;146(4), 439-47.
37. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
38. Camp NJ, Lin W, Bigelow A, Burghel GJ, Mosbruger T, Parry M, Waller R, Rigas SH, Rajamanickam V, Cosby R, Brock IW, Jones B, Connley D, Sargent R, Wang G, Cannon-Albright LA, Werner TL, Factor RE, Bernard P, Knight S, Abo R, Reed MWR, Gertz J, Cox A (2016). Discordant Haplotype Sequencing Identifies Candidate Functional Variants from Disease-Association studies: Breast Cancer Risk at 2q33. doi: 10.1158/0008-5472.CAN-15-1629. PMID: 26795348. Cancer Res, 76(7), 1916-25.
39. Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
40. Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
41. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol, 138(3), 513-8.
42. Lum MM, Belnap TW, Frandsen J, Brown AP, Sause WT, Soisson AP, Dodson MK, Werner T, Gaffney DK (2015). Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer. Am J Clin Oncol, 38(3), 283-8.
43. Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9.
44. Grenache DG, Heichman KA, Werner TL, Vucetic Z (2015). Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clin Chim Acta, 438, 358-63.
45. Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL (2014). State of the science in cervical cancer: where we are today and where we need to go. Cancer, 120(15), 2282-8.
46. Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ (2014). Primary non-Hodgkin lymphoma of the ovary. Semin Oncol, 41(3), e19-30.
47. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M (2013). Ovarian cancer, version 2.2013. J Natl Compr Canc Netw, 11(10), 1199-209.
48. Horvath LE, Werner T, Boucher K, Jones K (2013). The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses, 80(5), 684-7.
49. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA (2012). Ovarian cancer, version 3.2012. J Natl Compr Canc Netw, 10(11), 1339-49.
50. Albright F, Teerlink C, Werner TL, Cannon-Albright LA (2012). Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer, 12, 138.
51. Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, OMalley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL (2011). Epithelial ovarian cancer. J Natl Compr Canc Netw, 9(1), 82-113.
52. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK (2010). A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys, 78(1), 127-35.
53. Montejo M, Werner TL, Gaffney D (2009). Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev, 61(10), 883-9.
54. Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol, 82(4), 295-8.
55. Lo T, van Der Schalie E, Werner T, Brun YV, Din N (2004). A temperature-sensitive mutation in the dnaE gene of Caulobacter crescentus that prevents initiation of DNA replication but not ongoing elongation of DNA. J Bacteriol, 186(4), 1205-12.

Review

1. Williams NL, Werner TL, Jarboe EA, Gaffney DK (2015). Adenocarcinoma of the cervix: should we treat it differently? [Review]. Curr Oncol Rep, 2015 Apr, 17(4):17.
2. Lim HY, Werner T, Agarwal N, Rodgers GM (2008). Management of thrombotic microangiopathy with underlying malignancy. Helix Review Series: Oncology. 2008; 13(2):18-21. [Review]. 13(2), 18-21.

Book Chapter

1. Werner TL (December 2015). Chapter 4 - Breast Cancer Bone Metastases. In R. Lor Randall (Ed.), Metastatic Bone Disease: Essentials for the Orthopedic Surgeon (pp. 45-54). Springer International.

Conference Proceedings

1. Dang C, Ewer MS, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, de la Cruz Merino L, Lucas J, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Eng-Wong J, Swain SM (2017). Safety of adjuvant treatment with pertuzumab plus trastuzumab after neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive localized breast cancer: Updated results from the BERENICE study. 2017 San Antonio Breast Cancer Symposium.

Case Report

1. Tantravahi SK, Werner TL (2012). Locally recurrent endometrial cancer: a case report. J Natl Compr Canc Netw, 10(4), 442-5.
2. Wong J, Werner TL (July 2011). Kikuchi-Fujimoto Lymphadenitis: A Case of Misdiagnosed Breast Cancer. Am J Case Rep, 12, 80-82.
3. Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5.

Letter

1. Camp NJ, Werner TL, Cannon-Albright LA (2008). Familial myeloma. [Letter to the editor]. N Engl J Med, 359(16), 1734-5; author reply 1735.

Abstract

1. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. https://doi.org/10.1186/s12885-021-08242-4 [Abstract]. 21, 510.
2. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Ben-Baruch N, Werner TL, Oaknin A, Nam JH, Leath CA, Nicum S, Cella D, Sullivan DM, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA (2019). VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy+maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin [Abstract]. 30, 895-896.
3. Kingsford R, Pitt D, Low S, Weaver L, Moehle J, Cohen Al, Werner TL (2018). How to Be a Principal Investigator: Developing and Implementing of a Practical Training Program [Abstract]. 10th Annual AACI CRI Meeting Abstract Template.
4. Pant S, Spira AI, Cho SBC, Goel S, Hoimes CJ, Alva AS, Balaraman R, Bauer TM, Lowry PA, Ramaekers RC, Siegel RD, Werner TL, Tannir NM, Faltaos D, Potvin D, Neuteboom ST, Christensen J, Chao RC, Kyriakopoulos C (2018). Evalution of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT) [Abstract]. J Clin Oncol, 36.
5. Cohen AL, Neumayer L, Boucher K, Factor R, Shtrestha G, Wade M, Lamb G, Arbogast Ky, Piccolo S, Riegert J, Schabel M, Bild A, Werner TL (4/2017). A Window of Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker [Abstract]. JCO Precision Oncology, 1(April 2017), 1-11.
6. Cohen A, Neumayer L, Factor R, Boucher K, Wade ML, Lamb JG, Arbogast K, Piccolo S, Shrestha G, Riegert J, Schabel M, Bild A, Werner TL (2016). A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abst 1084.
7. Bauer T, Adkins D, Schwartz GK, Werner TL, Alva AS, Hong DS, Carvaja RD, Saleh MN, Bazhenova L, Goel S, Eaton KD, Siegel RD, Wang D, Lauer RC, Neuteboom STC, Faltaos D, Chen I, Christensen J, Chao RC, Heist RS (2016). A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2575.
8. Werner T, Sachdev J, Swisher E, Gutierrez M, Kittaneh M, Stein M, Xiong H, Dunbar M, Sullivan D, Ansell P, Hetman R, Komarnitsky P, McKee M, Tan A (2016). Veliparib (ABT-888) extended-release formulations: a phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 2579.
9. Boothe D, Williams, N, Odel B, Poppe M, Werner TL, Suneja G, Gaffney D (2016). The addition of adjuvant chemotherapy to radiation in high risk endometrial cancer: Survival outcomes and patterns of care. [Abstract]. J Clin Oncol, 2016 ASCO Annual Meeting, 34(2016), suppl;abstr 5587.
10. Munster P, VanDer Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (2015). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria. [Abstract]. European Society of Medical Oncology. [Abstract]. Clinical Cancer Research.
11. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R (2015). A Phase II Trial of Trebananib (AMG 386; IND#111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium: A Gynecologic Oncology Group Study [Abstract]. SGO March 2015, 137(supp 1), 24.
12. Diamond JR, Agarwal N, Bowles DW, Lan ET, Werner TL, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib and paclitaxel (PTX) in patients (pts) with advanced solid tumors [Abstract]. ASCO Annual Meeting, 2014, Chicago, Illinois.
13. Cohen AL, Factor R, Schabel M, Bild A, Werner TL (2013). Effect of short course, high-dose valproic acid on proliferation in breast adenocarcinomas. [Abstract]. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Abstracts 31:15s, 2013(May 20 Supplement), e13522.
14. Gaffney DK, Werner TL (2012). Curative Treatment for Recurrent and Metastatic Cervical Cancer [Abstract]. Expert Rev Obstet Gynecol, 7(6), 521-523.
15. Smit WS, Sufliarsky J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Spirtos N, Oza A, Dirix L, El-Hashimy M, Acharyya S, Tan EY, Weber D, Schellens JH (2012). A phase II study of Patupilone (EPO906) in patients with platinum- resistant or -refractory ovarian cancer. January 2012. [Abstract]. Clin Ovarian Cancer Other Gynecol Malig.
16. Agarwal, N, Sahu M, Abhyankar J, Werner TL, Benjamin B, Srinivas NR, Sharma S (June 2011). A drug-drug interaction study of Everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2011. Published in J Clin Oncol 29:15s, 2011 (suppl; abstr e15077). [Abstract]. Journal of Clinical Oncology, 29(15s).
17. Cohen, AL, Schabel M, Bild AH, Werner TL (2011). VAST (Valproic Acid Signature Trial): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. Poster Presentation Oncology Annual Meeting, Chicago, Illinois, June 2011. (suppl; abstr TPS148) [Abstract]. J Clin Oncol, 29(15s).
18. Bild AH, Sun Y, Soldi R, Conner T, Walker D, Werner T, Spira A, Andrulis I, Buys SS, Johnson E (2009). A Genomic Biomarker for Breast Cancer Development in High-Risk Women. Poster Presentation. CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2009. Published in Cancer Res 2009; 69(Suppl.): (24). Dec 15, 2009. [Abstract]. Cancer Res, 69(24).
19. Smit WM, Sufliarksy J, Werner TL, Dizon D, Wagnerova M, Hirte HW, Delaney R, Li J, Weber D, Schellens JH (2009). A phase II study evaluating the safety and efficacy of Patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 2009. Published in J Clin Oncol 27:15s, 2009 (suppl; abstr 5563). [Abstract]. Journal of Clinical Oncology, 27(15s), 5563.
20. Horvath LE, Werner T, Jones K (2007). The Relationship between Tumor Size and Stage in Early versus Advanced Ovarian Cancer: A Retrospective Chart Review. Poster Presentation. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2007. Published in J Clin Oncol, 25:18s, 2007 (suppl; abstr 5580). [Abstract]. Journal Of Clinical Oncology, 25(18s), 5580.

Other

1. Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P (2019). Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer (7(1), p. 46). England.